Non-alcoholic steatohepatitis (NASH) is a disease whose incidence is rising and is related to an accumulation of fat in the liver that can lead to its disfunction due to excessive inflammation and fibrosis. No medical treatments yet exist for NASH but it’s a hopeful time for the field because several drug candidates are in phase 2 and 3 clinical trials. New NASH drug targets are also being revealed due to progress in the fields of NASH contributors: metabolic disfunction, inflammation and fibrosis. Significant challenges remain, however, such as the need for non-invasive biomarkers and better models for the disease. At Cambridge Healthtech Institute's Targeting NASH conference, join academic and industry investigators to learn and discuss with one another drug development progress, challenges and solutions in the arena of treating fatty liver disease.
NASH DRUG CANDIDATES
FEATURED PRESENTATION: MGL-3196, a β-selective Thyroid Hormone Receptor (THR) Agonist
Rebecca Taub, MD, CMO & Executive Vice President, R&D, Madrigal Pharmaceuticals
FEATURED PRESENTATION: Parallel Development of Elafibranor and an in vitro Diagnostic (IVD) to Identify Patients for Drug Therapy
Dean Hum, PhD, CSO and COO, Genfit
Combinations with ACC Inhibitor for Treating NASH
Archana Vijayakumar, PhD, Research Scientist, Fibrosis, Gilead
NASH DRUG DEVELOPMENT CHALLENGES
Are Circulating Fibrosis Biomarkers Useful in NASH Drug Development?
Saurabh Gupta, PhD, Director, Translational Medicine and Early Clinical, Takeda Pharmaceuticals International Co.
Federal Landscape for NASH Patients and Products
Barrett Thornhill, JD, Executive Director, NASH Alliance
Drug Development for NASH Cirrhosis
Peter Traber, MD, Partner, Alacrita Consulting; Adjunct Professor of Medicine, University of Pennsylvania School of Medicine
NEW DRUG TARGETS OR EARLIER STAGE COMPOUNDS FOR LIVER DISEASE
Targeting Fructose Metabolism: Update on KHK inhibitor for NASH
Kendra K. Bence, PhD, Senior Director, Metabolism, Internal Medicine Research Unit (IMRU), Pfizer Inc.
Targeting GLP-1 for NASH
Karin Conde-Knape, PhD, Corporate Vice President, Cardiovascular and Liver Disease Research, Novo Nordisk
Targeting Integrin αVβ1 for the Treatment of Liver Fibrosis Associated with NASH
Eric Lefebvre, PhD, CMO, Pliant Therapeutics
* The program is subject to change without notice, due to unforeseen reason.